Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.47 |
| ▸ | DNMT3L | Q9UJW3 | 1/20 | 0.47 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.45 |
| ▸ | AGPAT2 | O15120 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4012756 | 0.86 | RAB9A (0.71) | RAB9ACYP1A2NPC1CYP3A4CYP2C19 | |
| SCHEMBL4212835 | 0.86 | NPC1 (0.58) | RAB9ACYP1A2NPC1CYP3A4CYP2C19 | |
| SCHEMBL18153382 | 0.83 | POLB (0.57) | RAB9ACYP1A2NPC1CYP3A4CYP2C19 | |
| SCHEMBL12218261 | 0.83 | RAB9A (0.76) | RAB9ACYP1A2NPC1CYP3A4CYP2C19 | |
| SCHEMBL18153334 | 0.80 | ABCG2 (0.63) | RAB9ACYP1A2NPC1CYP3A4CYP2C19 | |
| SCHEMBL4813491 | 0.79 | RAB9A (0.53) | RAB9ACYP1A2NPC1CYP3A4CYP2C19 | |
| SCHEMBL13039513 | 0.78 | DOT1L (0.74) | RAB9ACYP1A2NPC1CYP3A4CYP2C19 | |
| SCHEMBL21573639 | 0.77 | CYP1A2 (0.48) | RAB9ACYP1A2NPC1CYP3A4CYP2C19 | |
| SCHEMBL3958184 | 0.75 | ABCG2 (0.68) | RAB9ACYP1A2NPC1CYP3A4CYP2C19 | |
| SCHEMBL23999931 | 0.74 | RAD52 (0.52) | RAB9ACYP1A2NPC1CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118338898-A | Small molecule inhibitors of oncogenic CHD1L with preclinical anti-colorectal cancer activity | 科罗拉多州立大学董事会（法人团体） | 2024-07-12 | — | — | CN | disclosed |
| WO-2023055763-A2 | SMALL MOLECULE INHIBITORS OF ONCOGENIC CHD1L WITH PRECLINICAL ACTIVITY AGAINST COLORECTRAL CANCER | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2023-04-06 | — | — | WO | disclosed |
| US-20230103444-A1 | SMALL MOLECULE INHIBITORS OF ONCOGENIC CHD1L WITH PRECLINICAL ACTIVITY AGAINST COLORECTAL CANCER | UNITED STATES GOVERNMENT | 2023-04-06 | — | — | US | disclosed |
| EP-4127209-A2 | SMALL MOLECULE INHIBITORS OF ONCOGENIC CHD1L WITH PRECLINICAL ACTIVITY AGAINST COLORECTAL CANCER | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2023-02-08 | — | — | EP | disclosed |
| CN-115667553-A | Small molecule inhibitors of oncogenic CHD1L with preclinical activity against colorectal cancer | 科罗拉多州立大学董事会法人团体 | 2023-01-31 | — | — | CN | disclosed |
| WO-2021195279-A2 | SMALL MOLECULE INHIBITORS OF ONCOGENIC CHD1L WITH PRECLINICAL ACTIVITY AGAINST COLORECTAL CANCER | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2021-09-30 | — | — | WO | disclosed |
| WO-2021195279-A2 | SMALL MOLECULE INHIBITORS OF ONCOGENIC CHD1L WITH PRECLINICAL ACTIVITY AGAINST COLORECTAL CANCER | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2021-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230103444-A1 | SMALL MOLECULE INHIBITORS OF ONCOGENIC CHD1L WITH PRECLINICAL ACTIVITY AGAINST COLORECTAL CANCER | CHD1L, CHD1, CHD9 | RAB9A 581/4885CYP1A2 1999/4885NPC1 1745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.